Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.44 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.37 |
| ▸ | TRIM33 | Q9UPN9 | 1/20 | 0.37 |
| ▸ | HAVCR2 | Q8TDQ0 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | NUDT1 | P36639 | 2/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.31 |
| ▸ | PDE10A | Q9Y233 | 2/20 | 0.31 |
| ▸ | ATM | Q13315 | 1/20 | 0.31 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.31 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10290079 | 0.83 | EGLN2 (0.40) | EGLN2HAVCR2HSD17B10NUDT1ALDH1A1 | |
| SCHEMBL13390665 | 0.79 | NUDT1 (0.51) | EGLN2TRIM24TRIM33HSD17B10NUDT1 | |
| SCHEMBL3302899 | 0.79 | AHR (0.36) | TRIM24TRIM33NUDT1ALDH1A1ATM | |
| SCHEMBL2775804 | 0.78 | EGLN2 (0.42) | EGLN2ALDH1A1KMT2ASMN1; SMN2MAPK1 | |
| SCHEMBL2775808 | 0.78 | EGLN2 (0.42) | EGLN2ALDH1A1KMT2ASMN1; SMN2MAPK1 | |
| Formamide SCHEMBL28532491 | 0.77 | EGLN2 (0.43) | EGLN2NUDT1PDE10ACYP11B2 | |
| SCHEMBL258972 | 0.75 | EGLN2 (0.50) | EGLN2NPC1RAB9APDE10ACYP11B2 | |
| SCHEMBL543913 | 0.74 | EGLN2 (0.39) | EGLN2HSD17B10ALDH1A1PDE10ASMN1; SMN2 | |
| SCHEMBL543912 | 0.74 | EGLN2 (0.39) | EGLN2HSD17B10ALDH1A1PDE10ASMN1; SMN2 | |
| SCHEMBL10257434 | 0.73 | CA12 (0.43) | EGLN2ALDH1A1NPC1RAB9APDE10A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3728249-A1 | 1H -PYRAZOLO[4,3-b ]PYRIDINES AS PDE1 INHIBITORS | H. Lundbeck A/S (DK) | 2020-10-28 | — | — | EP | disclosed |
| US-10766893-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | H. LUNDBECK A/S (DK) | 2020-09-08 | — | — | US | disclosed |
| CN-111556871-A | 1H-pyrazolo [4,3-b ] pyridines as PDE1 inhibitors | H.隆德贝克有限公司 | 2020-08-18 | — | — | CN | disclosed |
| US-20190194189-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | H. LUNDBECK A/S (DK) | 2019-06-27 | — | — | US | disclosed |
| EP-2141150-B1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL (JP) | 2013-12-11 | — | — | EP | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-8110585-B2 | Bicyclic compound and pharmaceutical use thereof | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2012-02-07 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | TAKEDA PHARMACEUTICAL COMPANY LIMITED | 2010-05-27 | — | — | US | disclosed |
| EP-2141150-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-01-06 | — | — | EP | disclosed |
| EP-2141150-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | Takeda Pharmaceutical Company Limited (JP) | 2010-01-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10766893-B2 | 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors | PDE12, PDE3B, PDE5A | EGLN2 2488/4885TRIM24 1949/4885TRIM33 2808/4885 |
| US-20100130538-A1 | BICYCLIC COMPOUND AND PHARMACEUTICAL USE THEREOF | MTNR1A, MTNR1B, XDH | EGLN2 176/4885TRIM24 2377/4885TRIM33 4262/4885 |
| US-20190194189-A1 | 1H-PYRAZOLO[4,3-B]PYRIDINES AS PDE1 INHIBITORS | PDE12, PDE3B, PDE5A | EGLN2 2488/4885TRIM24 1949/4885TRIM33 2808/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.